Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Numinus Wellness Focused on Boosting Profitability and Expanding Community Support (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Surrozen Inc SRZN

Healthcare Biotechnology
Surrozen, Inc. is a clinical-stage biotechnology company. The Company is engaged in discovering and developing drug candidates to selectively modulate the Wnt pathway, a critical mediator of tissue repair, in a range of organs and tissues. The Company's lead product candidates are multi-specific, antibody-based therapeutics that mimic the roles of naturally occurring Wnt or R-spondin proteins... see more

Recent & Breaking News (NDAQ:SRZN)

Surrozen Publishes Article in Cellular and Molecular Gastroenterology and Hepatology Demonstrating that SZN-1326, a Selective Wnt Mimetic, Stimulated Robust Colon Epithelial Regeneration and Ameliorated Colitis in an Acute Model of Inflammatory Bowel Disease (IBD)

GlobeNewswire May 16, 2022

Surrozen Reports First Quarter 2022 Financial Results

GlobeNewswire May 11, 2022

Surrozen to Present at the BofA Securities 2022 Healthcare Conference

GlobeNewswire May 5, 2022

Surrozen Presents Data Supporting Potential of SZN-413 for the Treatment of Diabetic Retinopathy at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting

GlobeNewswire May 2, 2022

Surrozen Reports Fourth Quarter and Full Year 2021 Financial Results

GlobeNewswire March 24, 2022

Surrozen Announces Key 2022 Milestones for Lead Programs and Acceleration of Research Pipeline

GlobeNewswire January 10, 2022

Surrozen to Present Virtually at the 40th Annual J.P. Morgan Healthcare Conference

GlobeNewswire January 5, 2022

Surrozen Reports Third Quarter 2021 Financial Results

GlobeNewswire November 15, 2021

Surrozen Presents Data Supporting Potential of SZN-043 at The Liver Meeting 2021, the Annual Meeting of the American Association for the Study of Liver Diseases

GlobeNewswire November 15, 2021

Surrozen to Present at The Piper Sandler 33rd Annual Healthcare Conference

GlobeNewswire November 15, 2021

Surrozen to Present at The Stifel 2021 Virtual Healthcare Conference

GlobeNewswire November 5, 2021

Surrozen Presented Data Supporting Potential of SZN-1326 at the 2021 United European Gastroenterology Week

GlobeNewswire October 5, 2021

Surrozen Announces Appointment of Liz Nguyen as Vice President and Head of Human Resources

GlobeNewswire September 23, 2021